Asia · Regional markets · The Investor

Samsung Bioepis secures 10-year biosimilar supply deal in Brazil

Published by The Investor · South Korea 20 h ago

Samsung Bioepis said Tuesday it has secured a 10-year deal to exclusively supply its rare disease biosimilar SB12 to Brazil's public health system, strengthenin ...

Read the full article on The Investor Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.theinvestor.co.kr)

Also worth reading

Mint

Eternal share: What to expect from Zomato parent’s Q2 results 2026 as Blinkit growth stays strong

CNBC-TV18

US markets set to open lower as AI stocks slide and oil tops $100

The Straits Times Business

Monetary policy could turn accommodative as AI productivity gains take hold: MAS chief economist

The Business Times

Faster delivery, easier credit fuel South-east Asia e-commerce: survey

Business Standard

Artha Bharat to shift two GIFT City funds to Abu Dhabi over tax hurdles

Tech in Asia